Regeneron Posts $18.45 Q3 EPS as Shares Sit Near 52-Week High
REGN sits 41% above its 52-week low of $591.52.
Summary
Regeneron reported third-quarter adjusted EPS of $20.07, a step up from the $14.29 non-GAAP EPS it posted for Q2 2026, alongside net income of $1.95B on revenue of $5.12B, with revenue up 36% and non-GAAP EPS up 70%. Dupixent global net sales recorded by Sanofi rose 35% to $6.5B, and Eylea HD U.S. net sales rose 62% to $699M. The print lands with the stock at $835, just below its 52-week high of $859.34, so expectations were already elevated. The quarter follows a heavy stretch of pipeline news — FDA approval of Pasatru in August, the expanded Sanofi antibody collaboration in October, and positive COURAGE and ubamatamab data — giving the beat a broader commercial-plus-pipeline backdrop. Regeneron now sees 2026 adjusted gross margin of about 86%, up from its prior view of 84%-85%.
At the time of this announcement, REGN was trading at $835.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3B. The 52-week trading range was $591.52 to $859.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.